BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26055281)

  • 1. [Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social].
    Pérez-Rodríguez G
    Cir Cir; 2015; 83(3):193-8. PubMed ID: 26055281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
    Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
    Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and prognostic characteristics of the molecular subtypes of breast cancer determined by immunohistochemistry. Arequipa, Peru].
    Bueno GAM
    Rev Peru Med Exp Salud Publica; 2017; 34(3):472-477. PubMed ID: 29267772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
    Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo].
    Valle-Solís AE; Miranda-Aguirre AP; Mora-Pérez J; Pineda-Juárez JA; Gallardo-Valencia LE; Santana L; Cervantes-Sanchez G; Cárdenas-Cárdenas E
    Gac Med Mex; 2019; 155(Suppl 1):S50-S55. PubMed ID: 31182881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtypes of breast carcinoma in Saudi Arabia. A retrospective study.
    Alnegheimish NA; Alshatwi RA; Alhefdhi RM; Arafah MM; AlRikabi AC; Husain S
    Saudi Med J; 2016 May; 37(5):506-12. PubMed ID: 27146612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical profile and clinical-pathological variables in breast cancer.
    Cintra JR; Teixeira MT; Diniz RW; Gonçalves Junior H; Florentino TM; Freitas GF; Oliveira LR; Neves MT; Pereira T; Guerra MR
    Rev Assoc Med Bras (1992); 2012; 58(2):178-87. PubMed ID: 22569612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
    Vallejos CS; Gómez HL; Cruz WR; Pinto JA; Dyer RR; Velarde R; Suazo JF; Neciosup SP; León M; de la Cruz MA; Vigil CE
    Clin Breast Cancer; 2010 Aug; 10(4):294-300. PubMed ID: 20705562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on clinicopathological classification and clinical and pathological characteristics in breast cancer].
    Hu H; Liu Q; Xu L; Ye J; Zhao J; Duan X; Liu Y
    Zhonghua Wai Ke Za Zhi; 2014 Feb; 52(2):113-6. PubMed ID: 24809519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
    García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
    Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological classification and traditional prognostic indicators of breast cancer.
    Li J; Chen Z; Su K; Zeng J
    Int J Clin Exp Pathol; 2015; 8(7):8500-5. PubMed ID: 26339424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and correlation of molecular subtypes of breast cancer with clinicopathological features.
    Akbar M; Akbar K; Naveed D
    J Ayub Med Coll Abbottabad; 2014; 26(3):290-3. PubMed ID: 25671929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype.
    Cruz Ciria S; Jiménez Aragón F; García Mur C; Esteban Cuesta H; Gros Bañeres B
    Radiologia; 2014; 56(6):524-32. PubMed ID: 23294850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.